Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151133 | 0.88 | SIGMAR1 (0.45) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14774848 | 0.73 | DRD2 (0.50) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4144978 | 0.73 | ALDH1A1 (0.46) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1507019 | 0.71 | HRH3 (0.52) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL8117468 | 0.70 | MAPT (0.67) | SIGMAR1 | |
| SCHEMBL3780476 | 0.69 | HRH3 (0.56) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL11278990 | 0.69 | SIGMAR1 (0.60) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2794745 | 0.68 | TACR1 (0.55) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11888852 | 0.67 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL2359969 | 0.67 | SIGMAR1 (0.73) | SIGMAR1DRD2GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1423391-B8 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1423391-B1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | SIGMAR1 4770/4885DRD2 4870/4885GRIN2D 4760/4885 |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | CTSK, CTSS, CTSZ | SIGMAR1 4770/4885DRD2 4870/4885GRIN2D 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.